Novo Nordisk Pharmatech A / S is pleased to announce the opening of a new branch in Singapore at 152 Beach Road #17-04 The Gateway East, which opened on September 2019.
Novo Nordisk Pharmatech will host a Grand Opening on 15 October to celebrate together with customers, employees and other stakeholders. The Singapore location marks the first branch office for Novo Nordisk Pharmatech which celebrated its 70th anniversary this January.
Rasmus Hother le Fevre, managing director and corporate vice president of Novo Nordisk Pharmatech said: “We are thrilled to be expanding our footprint into Asia. This new office will serve as a hub to expand our business in Asia and it is in close proximity to some of the world’s leading biopharmaceutical companies. The location will give us access to a very large pool of the biopharmaceutical development in the region which is a key focus of the company.
“Our new Singapore location extends Novo Nordisk Pharmatech’s heritage of delivering high quality quaternary ammonium compounds as well as recombinant insulin for cell culture media to the pharmaceutical and biopharmaceutical industry.
“A local Singapore branch office was a logical step in our business growth strategy and presents a unique opportunity for Novo Nordisk Pharmatech to strengthen our presence. We have been active in this thriving market for several years. The local office in Singapore will allow us to serve both local companies in Singapore as well the rest of the Asian markets much more efficiently.”
To find out more, please fill out the enquiry form attached to this page.